Orkambi

Read about Orkambi, which combines ivacaftor with lumacaftor, and find out how the drug could help to treat people with cystic fibrosis (CF).

  • What is Orkambi?

    Orkambi is made up of ivacaftor and lumacaftor. The treatment has been shown to be effective in people with CF with two copies of the F508del mutation, which around 50% of people with CF in the UK have.

  • What effect does Orkambi have?

    96-week data shows that Orkambi can slow decline in lung function – the main cause of death among people with cystic fibrosis – by 42%.

Fighting for life-saving drugs

Find out more about our campaign to ensure that people with CF across the UK can have access to innovative precision medicines.

Tell me more

Join a campaign

Sign up to our campaigning mailing list and we'll keep you up to date on the CF campaigns you're interested in and the campaign actions relevant to you.

Sign up

Campaign timeline

Find out what's been happening in our campaign for life-saving drugs since it began in 2015.

Catch up